NCT04557150已完成1 期
An Open-Label, Multicenter, Phase I Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig (RO7425781) in Participants With Relapsed or Refractory Multiple Myeloma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 225
- 试验地点
- 40
- 主要终点
- Percentage of Participants with Dose Limiting Toxicities (DLTs)
研究概览
简要总结
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or who are intolerant to those established therapies. The study consists of two parts: dose-escalation of forimtamig (Part 1) and a randomized dose expansion of forimtamig (Part 2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previously diagnosed with Multiple Myeloma (MM) based on standard criteria.
- •Dose Escalation Phase and Dose Expansion Phase: Participants with r/r MM who have previously received therapy with an Immunomodulatory drug (IMiD) and Proteasome Inhibitor (PI) and are intolerant to or have no other option for standard-of-care treatment according to the Investigator.
- •Life expectancy of at least 12 weeks.
- •Agreement to provide protocol-specific biopsy material.
- •AEs from prior anti-cancer therapy resolved to Grade =<
- •Measurable disease.
- •For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse), use contraceptive measures and refrain from donating eggs.
- •For male participants: agreement to remain abstinent (refrain from heterosexual intercourse), use contraceptive measures and refrain from donating sperm.
排除标准
- •Inability to comply with protocol-mandated hospitalization and activities restrictions.
- •Pregnant or breastfeeding or intending to become pregnant during the study or within 3 months after last dose of study drug.
- •Prior use of any monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate for MM treatment within 2 weeks before first forimtamig administration.
- •Prior treatment with systemic immunotherapeutic agents within 2 weeks before first forimtamig administration.
- •Treatment-related, immune-mediated AEs associated with prior immunotherapeutic agents.
- •Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 2 weeks, prior to first forimtamig administration. Limited field palliative radiotherapy for bone pain or for soft tissue lesions is allowed.
- •Autologous or allogeneic stem cell transplantation (SCT) within 100 days prior to first forimtamig infusion and/or signs of chronic graft versus host disease or ongoing immunosuppressive medication.
- •Prior solid organ transplantation.
- •Active auto-immune disease or flare within 6 months prior to start of study treatment
- •Any medical condition or abnormality in clinical laboratory tests that, in the Investigator's or Medical Monitor's judgment, precludes the participant's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results.
研究组 & 干预措施
Part I: Dose Escalation
Experimental
Participants will receive forimtamig as intravenous (IV) infusion and/or subcutaneous (SC) injection in a step-up dosing fashion.
干预措施: Forimtamig (Drug)
Part II: Dose Expansion
Experimental
Dose Expansion cohorts with IV and/or SC administration, respectively, will be initiated at the Recommended Phase 2 Doses (RP2Ds) determined in Part I: Dose Escalation phase.
干预措施: Forimtamig (Drug)
结局指标
主要结局
Percentage of Participants with Dose Limiting Toxicities (DLTs)
时间窗: Cycle 1 Day 1 up to Cycle 1 Day 35
Percentage of Participants with Adverse Events (AEs)
时间窗: Up to 104 weeks
次要结局
- Objective Response Rate (ORR)(Up to 104 weeks)
- Time of Maximum Concentration (Tmax) of Forimtamig(Up to 104 weeks)
- Volume of Distribution at Steady State (Vss) of Forimtamig (IV only)(Up to 104 weeks)
- Maximum Concentration (Cmax) of Forimtamig(Up to 104 weeks)
- SC Bioavailability (F) of Forimtamig(Up to 104 weeks)
- Duration of Response (DOR)(Up to 104 weeks)
- Area Under the Curve (AUC) at Various Time Intervals of Forimtamig(Up to 104 weeks)
- Progression-Free Survival (PFS)(Up to 104 weeks)
- Overall Survival (OS)(Up to 104 weeks)
- Percentage of Participants with Anti-Drug Antibodies (ADAs) to Forimtamig(Up to 104 weeks)
- Minimum Concentration (Cmin) of Forimtamig(Up to 104 weeks)
- Apparent Clearance (CL/F) of Forimtamig(Up to 104 weeks)
研究者
研究点 (40)
Loading locations...
相似试验
终止
1 期
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid TumorsSolid TumorsNCT05129280Hoffmann-La Roche23
尚未招募
1 期
IMM40H Phase I Dose Escalation and ExpansionTumorNCT05549557ImmuneOnco Biopharmaceuticals (Shanghai) Inc.16
已完成
1 期
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple MyelomaNCT04434469Genentech, Inc.27
已完成
1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid TumorsSolid TumorsNCT01577745MedImmune LLC58
已完成
1 期
A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid TumorsNeoplasmsNCT02219724Genentech, Inc.174